5 Stocks Pushing The Drugs Industry Lower

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 66 points (0.4%) at 14,999 as of Wednesday, July 3, 2013, 12:51 PM ET. The NYSE advances/declines ratio sits at 1,256 issues advancing vs. 1,690 declining with 89 unchanged.

The Drugs industry currently sits down 0.1% versus the S&P 500, which is up 0.2%. On the negative front, top decliners within the industry include Valeant Pharmaceuticals International ( VRX), down 1.1%, and Eli Lilly and Company ( LLY), down 0.9%. Top gainers within the industry include Vertex Pharmaceuticals ( VRTX), up 1.5%, Celgene Corporation ( CELG), up 1.2% and Biogen Idec ( BIIB), up 0.6%.

TheStreet would like to highlight 5 stocks pushing the industry lower today:

5. Dr. Reddy Laboratories ( RDY) is one of the companies pushing the Drugs industry lower today. As of noon trading, Dr. Reddy Laboratories is down $1.14 (-3.0%) to $37.08 on heavy volume. Thus far, 268,628 shares of Dr. Reddy Laboratories exchanged hands as compared to its average daily volume of 230,200 shares. The stock has ranged in price between $36.82-$37.32 after having opened the day at $36.97 as compared to the previous trading day's close of $38.22.

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company. It operates in three segments: Pharmaceutical services and Active Ingredients (PSAI), Global Generics, and Proprietary Products. Dr. Reddy Laboratories has a market cap of $6.5 billion and is part of the health care sector. Shares are up 14.8% year to date as of the close of trading on Tuesday. Currently there are 2 analysts that rate Dr. Reddy Laboratories a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Dr. Reddy Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Dr. Reddy Laboratories Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, Sanofi ( SNY) is down $0.53 (-1.0%) to $50.36 on light volume. Thus far, 324,657 shares of Sanofi exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $50.08-$50.64 after having opened the day at $50.38 as compared to the previous trading day's close of $50.89.

Sanofi researches, develops, manufactures, and markets healthcare products worldwide. The company operates through Pharmaceuticals, Human Vaccines, and Animal Health segments. Sanofi has a market cap of $138.5 billion and is part of the health care sector. Shares are up 7.5% year to date as of the close of trading on Tuesday. Currently there are 6 analysts that rate Sanofi a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Sanofi Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Teva Pharmaceutical Industries ( TEVA) is down $0.25 (-0.6%) to $38.79 on light volume. Thus far, 1.3 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 3.8 million shares. The stock has ranged in price between $38.64-$38.88 after having opened the day at $38.85 as compared to the previous trading day's close of $39.04.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $33.2 billion and is part of the health care sector. Shares are up 4.6% year to date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and 14 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a buy. The company's strengths can be seen in multiple areas, such as its attractive valuation levels, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Teva Pharmaceutical Industries Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Abbott Laboratories ( ABT) is down $0.56 (-1.6%) to $34.30 on heavy volume. Thus far, 6.7 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 7.1 million shares. The stock has ranged in price between $33.72-$34.72 after having opened the day at $34.72 as compared to the previous trading day's close of $34.86.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. Abbott Laboratories has a market cap of $54.6 billion and is part of the health care sector. Shares are up 6.4% year to date as of the close of trading on Tuesday. Currently there are 12 analysts that rate Abbott Laboratories a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Abbott Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity and reasonable valuation levels. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, a generally disappointing performance in the stock itself and feeble growth in the company's earnings per share. Get the full Abbott Laboratories Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Bristol-Myers Squibb Company ( BMY) is down $0.69 (-1.6%) to $43.30 on average volume. Thus far, 6.2 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 11.0 million shares. The stock has ranged in price between $42.96-$43.95 after having opened the day at $43.95 as compared to the previous trading day's close of $43.99.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $73.6 billion and is part of the health care sector. Shares are up 35.0% year to date as of the close of trading on Tuesday. Currently there are 8 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 11 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Bristol-Myers Squibb Company Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

It's Not Over Yet: Keep an Eye on FANG Stocks

It's Not Over Yet: Keep an Eye on FANG Stocks

5 Stocks That Are Screaming Buys Right Now

5 Stocks That Are Screaming Buys Right Now

Jim Cramer on the Markets: 2:45pm Is a Make or Break Level

Jim Cramer on the Markets: 2:45pm Is a Make or Break Level

Video: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

Video: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

Dow Sells Off as U.S. and China Trade Tensions Escalate

Dow Sells Off as U.S. and China Trade Tensions Escalate